The production of the Pentaxim five-component vaccine (the development of the French Sanofi) is planned to be localized in Russia next year, TASS reports citing Maxim Stetsyuk, executive director of the Nanolek manufacturing company.
“We are in the localization process, our plans have moved a little bit to 2022,” Stetsyuk said as part of the Innoprom international industrial exhibition.
According to him, currently the production of the drug is localized in Russia by 30-40%. The vaccine is used to prevent diphtheria, tetanus, whooping cough, polio and hemophilic infection. Vaccine included in the Russian national calendar of preventive vaccinations.
